These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply. Gisbert JP; Chaparro M Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169 [No Abstract] [Full Text] [Related]
14. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases. Sanchez-Hernandez JG; Rebollo N; Munoz F; Martin-Suarez A; Calvo MV Ann Clin Biochem; 2019 Jan; 56(1):28-41. PubMed ID: 29807436 [TBL] [Abstract][Full Text] [Related]
15. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Van den Bosch F; Baeten D; Kruithof E; De Keyser F; Mielants H; Veys EM Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii33-6. PubMed ID: 11890649 [No Abstract] [Full Text] [Related]
16. Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model. Rowlinson-Busza G; Maraveyas A; Epenetos AA Br J Cancer; 1995 Apr; 71(4):660-5. PubMed ID: 7710925 [TBL] [Abstract][Full Text] [Related]
17. Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Deem RL; Shanahan F; Targan SR Clin Exp Immunol; 1991 Jan; 83(1):79-84. PubMed ID: 1899066 [TBL] [Abstract][Full Text] [Related]
18. Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment. Tsai TF Br J Dermatol; 2020 Jul; 183(1):7-8. PubMed ID: 32017027 [No Abstract] [Full Text] [Related]
19. Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained? Bar-Yoseph H; Chowers Y Aliment Pharmacol Ther; 2017 Jun; 45(11):1473-1474. PubMed ID: 28474829 [No Abstract] [Full Text] [Related]